|
Methylated primary ER-negative and ER-positive tumors: N0 and N1/N2 subgroups |
||||||
| N0 (n = 76) |
N1/N2 (n = 54) |
|||||
|
|
||||||
| Genes |
ER negative (n = 38) |
ER positive (n = 38) |
P valuea |
ER negative (n = 27) |
ER positive (n = 27) |
P valuea |
|
|
||||||
| RASSF1A |
18 (47%) |
36 (95%) |
<0.0001 |
18 (67%) |
24 (89%) |
0.0495 |
| CCND2 |
16 (42%) |
26 (68%) |
0.021 |
10 (37%) |
19 (70%) |
0.014 |
| GSTP1 |
1 (3%) |
7 (18%) |
0.025 |
3 (11%) |
12 (44%) |
0.0062 |
| TWIST |
11 (29%) |
17 (45%) |
NS |
6 (22%) |
15 (56%) |
0.012 |
| APC |
11 (29%) |
19 (50%) |
NS |
9 (33%) |
12 (44%) |
NS |
|
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant. | ||||||
Sunami et al. Breast Cancer Research 2008 10:R46 doi:10.1186/bcr2098 |
||||||